+ 86 (1812) 4514114 info@phcoker.com

Raa Avanafil uzuzu (330784-47-9)

A na-eji Avanafil ntụ ntụ agwọ ndị ikom nwere dysfunction (nke a na-akpọkwa enweghi ike mmekọahụ). Avanafil bụ otu …… ..


ọnọdụ: Na Production Production
Otu: 25kg / Drum
ikike: 1290kg / ọnwa

Description

Akwukwo uzo Avanafil (330784-47-9) video

Raa Avanafil uzuzu (330784-47-9) Nkọwa

Raw Avanafil ntụ ntụ bụ ihe ngosi PDE5 nke akwadoro maka dysfunction (ED: enweghi ike; enweghi ike ịnweta ma ọ bụ idobe ụmụ nwoke). Raw Avanafil ntụ ntụ na-eme ihe site na igbochi ihe nwere kpọmkwem phosphodiesterase 5 enzyme nke a na-ahụ na anụ ahụ dị iche iche, mana ihe bụ isi na akwara corpus cavernosum, yana retina. Ọ na - arụ ọrụ site na ịba ụba ọbara ọbara na amụ n’oge mkpali mmekọahụ. Ọgwụ ndị ọzọ yiri ya bụ sildenafil, tadalafil na vardenafil. Uru nke Raw Avanafil ntụ ntụ bụ na ọ nwere mmalite ngwa ngwa ngwa ngwa ma e jiri ya tụnyere ndị ọzọ na-egbochi PDE5. A na-adọrọ ya ngwa ngwa, na-ebute ntinye uche kachasị n'ihe dị ka nkeji 30 – 45. Ihe ụzọ abụọ n'ụzọ atọ nke ndị sonyere na-enwe ike itinye aka na mmekọahụ n'ime nkeji 15.

Raa Avanafil uzuzu (330784-47-9) Smmezi

Product Name Raw Avanafil uzuzu
Chemical Aha 330784-47-9;STENDRA; (s)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790; TA-1790
Brand Name Stendra na spedra
Klaasị ọgwụ ọjọọ PDE5 onye nhazi
CAS Number 330784-47-9
InChIKey WEAJZXNPAWBCOA-INIZCTEOSA-N
molekụla Fnhazi C23H26ClN7O3
molekụla Wasatọ 483.95
Nkịtị Monoisotopic 483.179 g / mol
Mgbu Point 150-152 ° C
Fna-agbanyeghachi Point Enweghị data dị
Ọkara Ndụ nke Ndụ Okpuru iwepu okara ndu = 5.36 - 10.66 awa
ọdịdị White ntụ ntụ
Sume DMSO, Methanol
Sịkwa akwa Tigwe Chekwaa na 4 Celsius C
ngwa Ihe mgbochi phosphodiesterase (PDE5), nke a na-eji dysfunction.

Raa Avanafil uzuzu (330784-47-9) Nkọwa

A na - eji Avanafil na - agwọ ọrịa dysfunction (ED: enweghi ike; enweghi ike ịnweta ma ọ bụ idobe ụmụ nwoke). Avanafil uzuzu nọ na klaasị nke ọgwụ akpọrọ phosphodiesterase (PDE) inhibitors. Ọ na - arụ ọrụ site na ịba ụba ọbara ọbara na amụ n’oge mkpali mmekọahụ. Mmụba ọbara a na-erugharị nwere ike ime ka mmadụ gbasaa. Avanafil ntụ ntụ anaghị agwọ ọnya ma ọ bụ nwekwuo agụụ mmekọahụ. Avanafil anaghị egbochi afọ ime ma ọ bụ mgbasa nke ọrịa ndị a na-ebute site na mmekọahụ dịka nje virus immunodeficiency ብቃት (HIV).

Azu Avanafil (330784-47-9) Ngosipụta nke Action

Avanafil bụ phosphodiesterase 5 (PDE5) enzyme inhibitor ejiri mee ihe maka ọgwụgwọ nke ọrịa dysfunction kpatara ọrịa shuga, nrụgide nke afọ iji akpata oxidative ma ọ bụ nsogbu ndị ọzọ. Avanafil na-egbochi cGMP kpọmkwem phosphodiesterase ụdị 5 (PDE5) nke bụ maka mbibi nke cGMP na corpus cavernosum nke dị n'akụkụ amụ. A na - eme ka penile erection n'oge mkpali mmekọahụ na - eme ka ọbawanye n'ọbara nke penile na - esite na izu ike nke akwara ozi na akwara anụ ahụ dị nwayọ. A na-emegharị nzaghachi a site na mwepụta nitric oxide (NO) site na njedebe akwara na mkpụrụ ndụ endothelial, nke na-akpali njikọta nke cGMP na mkpụrụ ndụ akwara dị mma. GMP cyclic na-eme ka izu ike nke akwara dị mma na mmụba ọbara na-abanye na corpus cavernosum. Ihe mgbochi nke phosphodiesterase ụdị 5 (PDE5) site na avanafil na-eme ka ọrụ dịkwuo elu site na ịba ụba ego nke cGMP.

Njikere Avanafil (330784-47-9)

A na-eji Avanafil ntụ ntụ agwọ ndị ikom nwere dysfunction (nke a na-akpọkwa enweghi ike mmekọahụ).

Na-atụ aro Avanafil ntụ ntụ (330784-47-9) Ụdị

Nye ọtụtụ ndị mmadụ, usoro a malitere atụ aro nke avanafil ntụ ntụ bụ 100 mg kwa ụbọchị were banyere 30 nkeji tupu oge mmemme. Dabere na nzaghachi nke nzaghachi ma ọ bụ mmetụta ndị dị na ya, a pụrụ itinye dose ahụ na 200 mg ma ọ bụ belata na 50 mg n'ụbọchị. Ndị ọ bụla na-aṅụ ọgwụ ndị na-eme ka ụbụrụ dị elu nke avanafil jiri nwayọọ nwayọọ na-ebute karịa dose 50 mg na 24 awa (Lee mmekọrịta ọgwụ ọjọọ).

Uru Avanafil uzuzu (330784-47-9)

Kwụsị iji avanafil ma kpọọ dọkịta gị n'otu oge ma ọ bụrụ na i nwere:

▪ mgbanwe nhụzi, ọhụụ mberede;

▪ na-adagharị na ntị gị, ma ọ bụ na mberede ụda ntị;

▪ mgbu, ọzịza, ọkụ, ma ọ bụ ọbara ọbara na otu ma ọ bụ abụọ ụkwụ;

▪ mkpụmkpụ nke iku ume, nkuba n'aka gị ma ọ bụ ụkwụ;

▪ mmetụta dị nro, dị ka ị nwere ike ịpụ; ma ọ bụ

▪ ime ụlọ nke na-egbu mgbu ma ọ bụ oge 4 dị ogologo ma ọ bụ karịa.

Mmetụta ndị na-emekarị nwere ike ịgụnye:

▪ isi ọwụwa;

▪ ịmegharị ọkụ (ọkụ, redness, ma ọ bụ obi ụtọ);

▪ mgbaàmà dị ichiiche dị ka mmiri na-agba agba ma ọ bụ na-adọrọ adọrọ, akpịrị akpịrị; ma ọ bụ

▪ ihe mgbu.

NKWUP ANDTA NA NKWU:

A na-ere Ihe Nke A Maka Nchọpụta Naanị. Usoro irere tinye. Ọbụghị maka Oriri mmadu, ma ọ bụ ọgwụ, ọgwụ anụ, ma ọ bụ nke ụlọ.


=

Ntughari & akwukwo akwukwo

Ajụjụ 9 jụọ onwe gị tupu iwere Avanafil

References

  1. Ryan M Burke, Jeffery D Evans, Avanafil maka ịgwọ ọrịa dysfunction: nyocha nke ike ya, Vasc Health Risk Manag. 2012; 8: 517 – 523.
  2. DeRogatis LR, Burnett AL. Akwukwo nso nke mmekorita nwoke na nwanyi. J Sex Med. 2008; 5: 289-300.
  3. Zhao C, Kim S, Yan D, et al. Ikike dị mma na nchekwa nke avanafil maka ịgwọ ọrịa dysfunction: nsonaazụ nke multicentre, nke a na-ahụ anya, nke gbara ya abụọ, na-achịkwa placebo. BJU Int. 2012 Mar 27;

Shangke Chemical bụ ụlọ ọrụ ọgbara ọhụrụ nke na-ahụ maka ndị na-ahụ maka ọgwụ na-arụ ọrụ (APIs). Iji chịkwaa àgwà n'oge mmepụta, ọnụ ọgụgụ buru ibu nke ndị ọkachamara nwere ahụmahụ, ngwá ọrụ mmepụta mbụ na ụlọ nyocha bụ isi ihe.

Kpọtụrụ Anyị